113 results about "Acquired immunodeficiency syndrome (AIDS)" patented technology

The compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof specifically binds CCR5, so it is useful for preventing and / or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection diabetes cancer metastasis and so on.Wherein all symbols in formula are as defined in the specification

The present invention relates to non-lethal methods of conditioning a recipient for bone marrow transplantation. In particular, it relates to the use of nonlethal doses of total body irradiation, total lymphoid irradiation, cell type-specific or cell marker-specific antibodies, especially antibodies directed to bone marrow stromal cell markers, NK cells, or the CD8 cell marker, cytotoxic drugs, or a combination thereof. The methods of the invention have a wide range of applications, including, but not limited to, the conditioning of an individual for hematopoietic reconstitution by bone marrow transplantation for the treatment of hematologic malignancies, hematologic disorders, autoimmunity, infectious diseases such as acquired immunodeficiency syndrome, and the engraftment of bone marrow cells to induce tolerance for solid organ, tissue and cellular transplantation.

The invention relates to an oxadiazole derivative, a preparation method therefor and use of the oxadiazole derivative in medicines. Particularly, the invention relates to an oxadiazole derivative represented by a general formula (I) shown in the description, a preparation method therefor, a pharmaceutical composition containing the derivative and use of the pharmaceutical composition in preparation of drugs for preventing and / or treating diseases with IDO mediated pathological features of a tryptophan metabolism pathway, wherein the diseases comprise cancer, Alzheimer's disease, autoimmune disease, melancholia, anxiety neurosis, cataract, psychological barrier and acquired immunodeficiency syndrome. Each substituent of the general formula (I) is the same as defined in the specification.

The invention discloses a compound with protein kinase inhibiting activity as well as a preparation method and application of the compound. The compound has a structure shown as a formula I, a formula II and a formula III. The compound provided by the invention can be used for medicines for treating cancers related with kinase inhibition, such as acute and chronic leukemia, lymphoma, breast cancer, lung cancer and sarcoma, and diseases including acquired immunodeficiency syndrome and Alzheimer's disease and the like. The invention further discloses the preparation method of the compound with the protein kinase inhibiting activity; the compound is produced through solid fermentation on rice by utilizing actinomyces; a fermented product is extracted through ethyl acetate and then is subjected to silica-gel column chromatography, gel column chromatography and reversed-phase chromatography separation and purification to obtain a product; the preparation method is easy to operate and implement. (The formula I, the formula II and the formula III are shown in the description.).

A compound represented by general formula (I):a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification. The compound of the present invention has antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

The invention relates to composite edible fungi polysaccharides and a preparation method thereof. The preparation method comprises the following steps: selecting fruiting bodies of Lentinus edodes, Auricularia aurlcula, Ganoderma lucidum and Grifola frondosa as raw materials; weighing at a ratio of (1:2):(2:1), mixing, pulverizing, adding distilled water, homogeneously mixing, and sequentially performing microwave extraction and condensation reflux extraction; separating residues and liquid; adding residues into distilled water, and sequentially performing microwave extraction and condensation reflux extraction for 1-2 times; mixing extractive solutions, carrying out vacuum concentrating until the volume of the extractive solution is 1 / 3-1 / 4 of the original volume; and precipitating with alcohols, vacuum drying, and pulverizing to obtain composite edible fungi polysaccharides. The composite edible fungi polysaccharides provided by the invention have good physiological activity and complete efficacy, and has the functions of resisting viruses, reducing blood lipid, regulating immune system, resisting platelet aggregation, resisting tumor, protecting liver, resisting gene mutation and resisting acquired immunodeficiency syndrome (AIDS) and the like. The preparation method of the composite edible fungi polysaccharides has the advantages of high yield of polysaccharides, reasonable process, and high operability.

The invention provides a CD4 protein-resistant monoclonal antibody and an active fragment and an application thereof. The antibody can be used for preventing a human immunodeficiency virus (HIV) from invading cells through combination with a human CD4 protein. The antibody can be used for detecting, diagnosing, preventing and treating diseases in which CD4 cells are taken as target cells, particularly an acquired immunodeficiency syndrome caused by the HIV. The invention further provides a relevant hybrid tumor cell strain, a separated nucleic acid molecule, a small peptide, a medicinal composition comprising the monoclonal antibody, and a kit.

The invention relates to a compound represented by formula (I):a salt thereof, an N-oxide thereof, or a solvate thereof (symbols in the formula are as described in the specification).The compound of the present invention exhibits very low risk of side effects and also has persistent and strong antagonistic activity against CXCR4, and is therefore useful as pharmaceuticals, for example, preventive and / or therapeutic agent for inflammatory and immune diseases, infections (for example, HIV infection), diseases associated with HIV infection (for example, acquired immunodeficiency syndrome (AIDS)), cancer, cancer metastasis, psychoneurotic diseases and cardiovascular diseases (for example, retinopathy), metabolic diseases, cancerous diseases, or an agent for regeneration therapy.

The present invention relates to a medicament comprising the compound of formula (I) wherein all symbols have the same meanings as defined in the specification, a salt thereof or a prodrug thereof. The compound of the present invention is useful for the prevention and / or treatment of immune diseases such as various types of inflammation, autoimmune disease, allergic diseases, etc.; infection concerning inflammation or HIV infections (e.g. asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), organ transplantation rejection, immunosuppression, psoriasis, multiple sclerosis, optic neuritis, polymyalgia rheumatica syndrome, uveitis, vasculitis, human immunodeficiency virus infection (acquired immunodeficiency syndrome etc.), atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, osteoarthritis, ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacteria infection, diabetes, cancer metastasis, atherosclerosis, etc.).

The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.

A method for preventing infection of helper T and other target cells by human immunodeficiency virus type 1 (“HIV-1”) and for preventing or treating acquired immunodeficiency syndrome (“AIDS”) by exposing target cells to a synergistic combination of at least one attachment inhibitor and at least one fusion inhibitor. The attachment inhibitors are compounds that bind to the CD4 receptor on target cells or that bind to gp120 on HIV-1, e.g., antibodies, and the fusion inhibitors compounds that interact with gp41 to inhibit or prevent its interaction with target cells, e.g., pentafuside.

The present invention concerns alkyl aryl carbonyl compounds that possess anti-infective activity. The compounds of the invention can be used to target specific nuclear localization signal, thereby blocking importation of specific proteins or molecular complex into the nucleus of a cell. The invention encompasses methods of use of such compounds for treatment or prevention of infectious diseases, such as parasitic and viral diseases, including, for example, malaria and acquired immunodeficiency syndrome. The use of the compounds to detect certain specific protein structures which are present in nuclear localization sequences is also taught.

The present invention relates to compositions comprising analogues of purine nucleosides containing a ring-expanded (“fat”) heterocyclic ring, in place of purine, and an unmodified or modified sugar residue, pharmaceutically acceptable derivatives of such compositions, as well as methods of use thereof. In particular, these compositions may be utilized in the treatment of certain cancers, bacterial, fungal, parasitic, and viral infections, including, but not limited to, Acquired Immunodeficiency Syndrome (AIDS), hepatitis, Epstein-Barr and cytomegalovirus.

The compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof specifically binds CCR5, so it is useful for preventing and / or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection diabetes cancer metastasis and so onWherein all symbols in formula are as defined in the specification.

A compound represented by general formula (I):a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and / or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

The present invention discloses a Chinese medicine extract for resisting acquired immunodeficiency syndrome (AIDS) virus and its preparation method. Said Chinese medicine extract is lonicera flower extract, and its preparation method includes the following steps: decocting lonicera flower in water, concentrating decoction to obtain extract, using acid to regulate pH value, filtering to remove impurity, collecting precipitate, using ethyl alcohol to wash said precipitate at twice, collecting granular precipitate, dissolving extract and granular precipitate, filtering and drying so as to obtain the invented product.

The invention discloses glycyrrhiza polysaccharide granules and a preparation method thereof; a tissue culture method is adopted to produce glycyrrhiza polysaccharide, and the glycyrrhiza polysaccharide granules can be prepared by the glycyrrhiza polysaccharide and other excipients. The glycyrrhiza polysaccharide granules comprise the components by parts: 100-150 parts of glycyrrhiza polysaccharide, 100-300 parts of sustained-release material, 100-200 parts of filler and 5-10 parts of adhesive. The glycyrrhiza polysaccharide is produced by being cultured by a fermentation tank; the developed glycyrrhiza polysaccharide granules are convenient to use and can be directly taken or taken with water; the produced glycyrrhiza polysaccharide has obvious immune dispensing activity and is capable of activating macrophage and tuberculosis (TB) lymphocyte, so that humoral immunity and cellular immunity can be enhanced, and the aims of improving the general immunity function and more effectively inhibiting tumours and acquired immunodeficiency syndrome (AIDS) can be achieved; furthermore, products developed by the polysaccharide have obvious health care function so as to have excellent develop space.

A production method of a functional beverage rich in selenium and strontium comprises the following steps: inoculating an aqueous solution containing molasses, amino acids and pantothenic acid as a medium with Bacillus subtilis, photosynthetic bacteria and lactic acid bacterium strains, placing the obtained solution in a fermentation tank, culturing for 5 d, immersing wheat seeds in a specially-prepared selenium and strontium culture solution for 24 h, culturing germs rich in selenium and strontium in a specially-produced temperature-controlled, humidity-controlled and light-controlled ultrasonic atomization biological culture box, carrying out a wall breaking emulsification treatment technology to directly prepare a chlorophyll nutrient solution rich in selenium and strontium, adding the chlorophyll nutrient solution rich in selenium and strontium to a red grape juice beverage to produce the ideal, safe and highly-efficient functional beautifying beverage being able to supplement selenium and strontium, wherein every 200 ml of the functional beverage contains 50-100 [mu]g of organic biological selenium, 1 mg of organic strontium, and is rich in chlorophyll, amino acids, SOD and other effective components. The functional beverage can be taken for a long term to realize beautifying, has an obvious anti-ageing effect, and also can prevent cancers, cardiovascular and cerebrovascular diseases, diabetes, hepatopathy, acquired immunodeficiency syndrome and other serious diseases.

The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.

The invention belongs to the field of biomedicines, relates to an anti-HIV (Human Immunodeficiency Virus) infection polypeptide, in particular to a polypeptide shown as a formula IY1-IXb1ELXe1BB-SXb2ELXe2BB-IXb3EXd3Xe3BB-Xa4Xb4EXd4Xe4BB-Y2 and a derivative, stereoisomer or salt without physiological toxicity thereof, and also relates to a medicinal composition comprising the polypeptide shown as the formula I and the derivative, stereoisomer or salt without physiological toxicity thereof and application of the polypeptide shown as the formula I and the derivative, stereoisomer or salt without physiological toxicity thereof to treatment or prevention of related diseases caused by HIV infection, in particular to acquired immunodeficiency syndrome (AIDS).

The invention discloses an RT / PR dual-target HIV inhibitor, a preparation method and applications thereof. According to the present invention, the RT / PR dual-target HIV inhibitor is prepared from a compound represented by a formula 1, or a pharmaceutically acceptable salt thereof, wherein the compound represented by the formula 1 has obvious inhibition activity on HIV reverse transcriptase and HIVprotease; and the toxicity study results show that the compound has good drug-forming property, such that the compound as the anti-acquired immunodeficiency syndrome drug has good application prospects. The formula I is defined in the specification.

Provided is a triterpene-polypeptide conjugate, stereoisomer or pharmaceutically acceptable salt thereof. Also provided are a pharmaceutical composition containing the conjugate, stereoisomer or pharmaceutically acceptable salt thereof, and use of the conjugate, stereoisomer or pharmaceutically acceptable salt thereof in treating or preventing related diseases caused by HIV infection, especially the acquired immunodeficiency syndrome (AIDS).

The invention relates to a preparation method of a drug for preventing and treating acquired immunodeficiency syndrome and an application thereof, and particularly relates to a preparation method of American ginseng extract, and an application thereof in preparation of the drug for preventing and treating the acquired immunodeficiency syndrome. The American ginseng extract is prepared into oral preparation or injection by adding a pharmaceutical acceptable carrier; and the dosage form of the oral preparation preferably is a capsule, a troche, a pill, a micro pill, oral liquid or granula. The pharmacodynamic test shows that the American ginseng extract can effectively prevent human immunodeficiency virus (HIV) infection under the premise of not damaging the immunologic function, and is free of side effect, so as to achieve prevention and treatment of the acquired immunodeficiency syndrome.

The invention discloses an efavirenz preparation adopting a micronization technology. The invention provides a modified efavirenz orally-taken preparation which is used for inhibiting human immunodeficiency virus (HIV), preventing or treating HIV infection, and treating acquired immunodeficiency syndrome (AIDS) caused by the HIV infection, and in particular relates to tablets or a capsule which comprises efavirenz, wherein a micronization technology which can promote the dissolution velocity of the efavirenz in gastrointestinal tract, so that the absorption velocity and the absorption extent of the efavirenz in bodies is involved.

The invention belongs to the field of biological medicine, relates to artificially designed HIV (human immunodeficiency virus)-infection-resisting polypeptide, in particular to polypeptide as shown in a formula I of Xa1AAXd1Xe1BB-Xa2AAXd2Xe2BB-Xa3AAXd3Xe3BB-Xa4AAXd4Xe4BB-Xa5AAXd5Xe5BB (formal I), and a derivative, a stereoisomer or physiological-toxicity-free salt thereof. The invention further relates to a pharmaceutical composition containing the polypeptide in the formula I and the derivative, the stereoisomer or the physiological-toxicity-free salt of the polypeptide, and application of the polypeptide in the formula I and the derivative, the stereoisomer or the physiological-toxicity-free salt of the polypeptide to treatment or prevention of related diseases and particular acquired immunodeficiency syndrome (AID) caused by HIV infection.

The invention relates to a device capable of realizing rapid dismantlement and adopting a dual drive coupling mode for diagnosing AIDS (Acquired Immunodeficiency Syndrome) and belongs to the field of analytical test. Technical barriers exist in a method of producing a substrate of a microfluidic chip for diagnosing the AIDS by using polydimethylsiloxane (PDMS) which is low in price and easy to process. For overcoming the barriers, the device is characterized in that the substrate selects the PDMS with an original ecological surface; an elastic force of a micro ultrasonic transducer is attached to a clamping arm of the substrate, and the substrate is occluded and located in a neighbor position of a sample liquid flow terminal of the micro-fluidic chip by using the elastic force; moreover, an ultrasonic attenuator is arranged at the sampling end of the micro-fluidic chip and used for realizing rapid attenuation of ultrasonic intensity in a short distance, so that interfacial tension difference is formed at two ends of the chip; the difference provides a strength for driving sample liquid flow to flow to the terminal direction along a hydrophobic capillary channel; the strength is also mutually coupled and collaboratively operates with mechanical pumping power of a micropump contained in the structure.